Statins and elevated liver tests: what's the fuss?

Comparison of Elevated Liver Enzymes in Type 2 Diabetic Patients in User and Non-User of Statin

Background: Type-2 diabetes is a risk factor for progressive non-alcoholic fatty liver disease and the majority of diabetic patients have blood lipid disorders, so they take statin drugs. Statins have the adverse effects such as liver dysfunction and increase in liver enzymes. The purpose of this study was to compare the liver enzymes in type 2 diabetic patients who are user and non-user of sta...

What's all the fuss about?

Treatment of hypercholesterolemia in patients with primary biliary cirrhosis might be more beneficial than indicated.

Cholesterol circulating levels are elevated in most of the patients with primary biliary cirrhosis. This review questions whether hypercholesterolaemia represents a cardiovascular risk in primary biliary cirrhosis and whether it should be treated. The published evidence indicates that hypercholesterolaemia in patients with primary biliary cirrhosis should be considered a cardiovascular risk fac...

Nonalcoholic fatty liver disease and statins.

OBJECTIVE Nonalcoholic fatty liver disease (NAFLD) is the most frequent cause of elevated transaminase levels and affects approximately one third of the general population. Patients with NAFLD are at increased risk for cardiovascular events, which represent the leading cause of death in this population. We discuss the safety and efficacy of statins in this population. MATERIALS/METHODS We rev...

What's all the fuss? Safety concerns about COX-2 inhibitors rofecoxib (Vioxx) and celecoxib (Celebrex).